9. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-9.
10. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21: 2324-32.
11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J
Francesco Montagnani, Greta Di Leonardo, Mariasimona Pino, Simona Perboni, Angela Ribecco and Luisa Fioretto
Angiogenesis is a critical step in colorectal cancer growth, progression and metastasization. The process of blood vessels formation involves many different molecules and pathways. Among these, the vascular endothelial growth factors (VEGFs) driven pathway is one of the most powerful and better studied.[ 1 ] VEGFs comprises a family of multiple growth factors that act through the activation of at least three different receptors.[ 2 ] In a landmark trial, the anti-VEGF-A monoclonal antibody bevacizumab improved progression-free survival (PFS
Eva Ogorevc, Veronika Kralj-Iglic and Peter Veranic
1. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009; 8: 2014-18.
2. Rak J. Microparticles in cancer. Semin Thromb Hemost 2010; 36: 888-906.
3. Pap E. The role of microvesicles in malignancies. Adv Exp Med Biol 2011; 714: 183-199.
4. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/ microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res 2011; 1: 98
Diabetes Int 25: 76–79, 2008.
11. ACCORD Study Group; ACCORD Eye Study Group, Chew EY et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363: 233–244, 2010.
Evelyn Nathalia, Madelaine Skolastika Theardy, Sharleen Elvira, Graciella Rosellinny, Andrew Steven Liyanto, Michael Putra Utama and Anton Sumarpo
developing palate . Orthod Craniofac Res. 2002; 5 (2):65-70.
24. MOHER D., LIBERATI A., TETZLAFF J., ALTMAN DG., PRISMA GROUP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement . PLoS Med. 2009; 6 (7):e1000097.
25. YANG J., HAN F., LIU W., ZHANG M., HUANG Y., HAO X., et al. LHX6, an independent prognostic factor, inhibits lung adenocarcinoma progression through transcriptional silencing of β-catenin . J Cancer. 2017; 8 (13):2561-2574.
26. HU Z., XIE L. LHX6 inhibits breast cancer cell proliferation and invasion
Sandra Hanysova, D. Cierny, E. Kurca and J. Lehotsky
, Lehotsky J. Genetic variants in interleukin 7 receptor chain (IL-7Ra) are associated with multiple sclerosis risk and disability progression in Central European Slovak population. J Neuroimmunol. 2015; 282: 80-4.
9. Čierny D, Michalik J, Kurča E, Dobrota D, Lehotsky J. FokI vitamin D receptor gene polymorphism in association with multiple sclerosis risk and disability progression in Slovaks. Neurol Res. 2015; 37 (4): 301-8.
10. Alexoudi A, Zachaki S, Stavropoulou C, Gavrili S, Spiliopoulou C, Papadodima S et al. Possible Implication of
Hanan R. Nassar, Alfred E. Namour, Hanan E. Shafik, Amr S. El Sayed, Samar M. Kamel, Manar M. Moneer and Nadia I. Zakhary
-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer. 2008; 8: 212-226.
 Rodrigues L, Jose´ A, Teixeira F, Schmitt L, Marie P. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(6): 1087-97.
 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010; Feb: 10(1): 71-81.
 Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF: The functional and
Background and aims: Transforming growth factor-beta 1 (TGF-β1) and vascular adhesion molecule 1 (VCAM-1) have been proposed as promising biomarkers for multiple diseases. TGF-β1 and VCAM-1 are reported to be associated with diabetic kidney disease (DKD) and end stage renal disease in patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM).
Material and methods: The aim of this study was to investigate the expression of circulating TGF-β1 and VCAM-1 and to assess their potential as a blood-based biomarker for DKD in T1DM and T2DM patients.
Results:. The study included 124 participants: 66 patients with T1DM, 58 with T2DM and 20 healthy controls. The diabetic patients were classified according to the estimated glomerular filtration rate (eGFR). First group - eGFR ≥90ml/min/1.73 m2 (n=39), second group eGFR 89-60 ml/min/1.73m2 (n=45), and third group eGFR 59-45 ml/min/1.73m2 (n=40). Enzyme-linked immunosorbent assay for the quantitative detection of was used to evaluate blood TGF-β1 and VCAM-1 expression. It was found that there were higher TGF-β1 and VCAM-1 in all diabetic patients compared with healthy controls (P<0.05). TGF- β1 and VCAM-1 were higher in group with eGFR ≥90ml/min/1.73 m2 and gradually increased in the groups with eGFR89-60 ml/min/1.73m2 and eGFR 59-45 ml/min/1.73m2. TGF- β1 and VCAM-1 were less in T1DM, than T2DM in all study groups. Regression analysis revealed reverse associations between TGF- β1, VCAM-1 and eGFR (P<0.05). TGF- β1 and VCAM-1 correlated positively with albuminuria and negatively with renal function.
Conclusion: In discriminating overall patients from healthy subjects, ROC analysis revealed areas under the curve (AUCs) of 1,0 for TGF- β1 for T1DM and T2DM, VCAM-1 0,866 for T1DM, 0,923 for T2DM (P<0.001). The results suggested that blood-based TGF- β1 and VCAM-1 may serve as potential biomarkers for early detection of DKD.
Borut Kobal, Marco Noventa, Branko Cvjeticanin, Matija Barbic, Leon Meglic, Marusa Herzog, Giulia Bordi, Amerigo Vitagliano, Carlo Saccardi and Erik Skof
residual disease = 0 in comparison to primary surgery. 9 , 10 , 11 Consequently, an approach based on NACT + IDS as first line treatment in all patients suffering by advanced stage EOC has been recently proposed and two randomized controlled studies have been published in order to compare survivals of PDS versus NACT + IDS strategy. 12 , 13 Both EORTC and the most recent CHORUS trial showed no differences in overall survival (OS) and progression free survival (PFS) in the two treatments arms. 12 , 13 However, concerns about the degree of evidence from these two
Diana-Silvia Zilişteanu, Teodora Atasie and M. Voiculescu
1. MASOLA V, ZAZA G, GAMBARO G. Sulodexide and glycosaminoglycans in the progression of renal disease . Nephrol Dial Transplant 2014; 29 : i74-i79.
2. LAUVER DA, LUCCHESI BR. Sulodexide: a renewed interest in this glycosaminoglycan . Cardiovascular Drug Reviews 2006; 24 (3-4): 214-226.
3. LAUVER DA, LUCCHESI BR. Sulodexide: A renewed interest in this glycosaminoglycan . Cardiovascular Drug Reviews 2006; 24 (3–4): 214–226. 2
4. MANELLO F, MEDDA V, LIGI D, RAFFETTO JD. Glycosaminoglycan sulodexide inhibition of MMP-9